TCR repertoires of PBMC and tumor from 31 GL261 glioma mice (128 samples)
The immune system functions as a primary safeguard against diseases, with the adaptive immune system using targeted mechanisms to fight against pathogens and cancer as well as in autoimmune or inflammatory diseases. This protective capability is achieved through recognition and response to a diverse array of antigens via the distinctive characteristics of an individual's T cell receptor (TCR) repertoire. Checkpoint immunotherapy enhances the immune system's ability to detect and destroy tumor cells - yet, predicting individual responses to these treatment remains a major challenge.We provide a comprehensive dataset of TCR repertoires from a syngeneic, orthotopic GL261 glioma mouse model. Mice were treated with anti-PD-1 antibodies or left untreated as controls, with longitudinal monitoring and sample collection extending to day 63 post-tumor implantation. Tumor progression was monitored non-invasively using bioluminescent imaging. In total, 128 samples were collected from peripheral blood mononuclear cells (PBMCs) and tumor tissues at multiple time points. TCR libraries were generated and sequenced for both alpha and beta chains. Approximately 30% of treated mice exhibited a therapeutic response, enabling comparative analysis between responders and non-responders.This dataset provide a suitable resoucse for investigating TCR-based biomarkers to predict immunotherapy responses. The inclusion of control, responder, and non-responder groups, along with longitudinal sampling from both blood and tumor tissues, offers unique opportunities to identify TCR signatures associated with treatment outcomes. These insights have the potential to advance personalized immunotherapeutic strategies and improve clinical decision-making in GBM cancer treatment.